Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Intraocular Pressure, Delivery
Phase NA
Enrollment 9
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Glaucoma is a multifactorial disease, an important risk factor of which is increased intraocular pressure. Fluctuations in intraocular pressure are often associated with vaginal birth, although intraocular pressure during active pushing during stage II has never been measured.. The study will be conducted on a group of patients with healthy eyes on patients who have completely fine vision or have a small refractive error and are accustomed to wearing contact lenses. The measurement of intraocular pressure itself will be carried out using SENSIMED Triggerfish contact lenses, which measure pressure every 5 minutes for 30s. This period roughly corresponds to the duration of 1-2 contractions. Inclusion in the study will be offered to patients in the 35th to 37th week of pregnancy. Prior to measurement patients will be sent to an eye clinic for a detailed examination of both eyes, which includes measuring intraocular pressure. Subsequently, pregnancy checks will take place according to the standard scheme and in the standard scope. At the onset of uterine contractions, an ophthalmologic consultant will be called, which will measure intraocular pressure between contractions using the Tonopen device and put on SENSIMED Trigerfish contact lenses in combination with a local anesthetic. The patient will have these lenses until the end of the third stage of labor, i.e. 2 hours after the birth, when the lenses are removed. In the second stage of labor, continuous monitoring by a cardiotocograph will take place. Subsequently, the obtained data from the cardiotocograph and contact lenses will be evaluated and compared by a team of ophthalmologists and gynecologists, where the investigators will be able to assess the individual fluctuations in intraocular pressure depending on the individual contractions. The aim of the study is to demonstrate or disprove the risks to the glaucoma patient due to increased intraocular pressure during active pushing in combination with uterine contraction.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: SENSIMED Triggerfish Eye Lenses — Contact lenses used for measuring intraocular pressure.

Primary Outcomes

  • Fluctuation of Intraocular pressure (From start of regular contractions for the length of 24 hours (at least 2 hours after delivery if patient complies about the lenses))
  • Rate of Uterine contractions (Continuous CTG will be done during II phase of delivery and at least every 2 hours durins I phase of delivery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-08
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 9 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Faculty Hospital Kralovske Vinohrady
Principal Investigators:
  • Pavel Studeny, prof, MD, Ph.D. (STUDY_CHAIR) - Fakultni Nemocnice Kralovske Vinohrady
Contact Information
Study Contact:
Jan Zapletal, MD
+420607882602
honza.zaple@seznam.cz
Alina Dana Baxant, MD
+420734395155
alinadana.baxant@fnkv.cz
Jan Zapletal, MD
+420607882602
honza.zaple@seznam.cz
Faculty Hospital Kralovske Vinohrady
Interventions
  • Device: SENSIMED Triggerfish Eye Lenses — Contact lenses used for measuring intraocular pressure.
Study Locations (1 sites)
Faculty Hospital Kralovske Vinohrady, Prague, 11000 Czechia
Eligibility Criteria
Inclusion Criteria: * physiological pregnancy * primiparous women Exclusion Criteria: * multiparous women * pathological pregnancy
Conditions Postoperative Pain Following Modified Ra...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This study compares two methods of local pain control in patients undergoing Modified Radical Mastectomy, a common surgery for breast cancer( tumor in the breast) treatment. It aims to determine which method, the Thoracic Interfascial Plane Block or the Erector Spinae Plane Block, provides better pain relief after surgery, reduces side effects, and increases patient satisfaction. Why This Study Is Important: Breast cancer surgery can cause significant pain, and managing this pain is important for a quick recovery. Currently, pain is often managed with opioids, which can cause side effects like nausea and drowsiness. invistigators want to find a method that controls pain effectively with fewer side effects, helping patients recover faster and feel better. Who Can Take Part: Women aged 21 and older who are scheduled for a Modified Radical Mastectomy at Ain Shams University hospitals can participate in this study. What Will Happen During the Study: Participants will be randomly assigned to receive either the Thoracic Interfascial Plane Block or the Erector Spinae Plane Block before surgery. Pain levels will be measured using a numerical pain score from 1 to 10. Researchers will track the amount of pain medication needed, the time it takes to feel pain relief, and any side effects. Other factors such as sleep quality, time to start walking again, and overall satisfaction with pain control will also be recorded. What investigators hope to Learn: Investigators hope to find out which nerve block provides better pain relief after surgery. By comparing TIPB and ESPB, with the aim to identify the method that: Requires less additional pain medication Has fewer side effects Improves sleep quality and overall recovery Increases patient satisfaction Significance: This study could lead to better pain management strategies for breast cancer surgery, reducing the need for opioids and enhancing patient recovery and comfort. Participation: Participants will be monitored closely during and after the procedure to ensure their safety and well-being. The results of this study could help improve pain management for future patients undergoing similar surgeries.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Procedure: Thoracic Interfascial Plane Block — The Thoracic Interfascial Plane Block (TIPB) is a regional anesthesia technique used to manage postoperative pain, particularly in thoracic and breast surgeries. This block involves the injection of a local anesthetic into the fascial plane between the thoracic muscles, targeting the nerves that supply the chest wall and upper abdominal area. It includes Pecto-Intercostal Fascial Plane Block (PIFB) and Serratus Intercostal Fascial Plane Block (SIFB).
  • Procedure: Erector Spinae Plane Block — The Erector Spinae Plane Block (ESPB) is a regional anesthesia technique used to manage pain, particularly in thoracic and abdominal surgeries. This block involves the injection of a local anesthetic into the plane between the erector spinae muscle and the transverse processes of the vertebrae.

Primary Outcomes

  • Total amount of rescue pain medication required within the first 48 hours after surgery (48 hours)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-01
Completion: 2025-03-15
Eligibility
Age: 21 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Safie ramez tewfeik abd el moneim
Contact Information
Study Contact:
Safie R Abd El Moneim, Masters
01280202299
safie.ramez@med.asu.edu.eg
Fatma Dr, Lecturer
26857539
rec-fmasu@med.asu.edu.eg
Ainshams University Hospitals
Safie R Abd El Moneim, Masters degree
Ainshams University Hospitals
Interventions
  • Procedure: Thoracic Interfascial Plane Block — The Thoracic Interfascial Plane Block (TIPB) is a regional anesthesia technique used to manage postoperative pain, particularly in thoracic and breast surgeries. This block involves the injection of a local anesthetic into the fascial plane between the thoracic muscles, targeting the nerves that supply the chest wall and upper abdominal area. It includes Pecto-Intercostal Fascial Plane Block (PIFB) and Serratus Intercostal Fascial Plane Block (SIFB).
  • Procedure: Erector Spinae Plane Block — The Erector Spinae Plane Block (ESPB) is a regional anesthesia technique used to manage pain, particularly in thoracic and abdominal surgeries. This block involves the injection of a local anesthetic into the plane between the erector spinae muscle and the transverse processes of the vertebrae.
Study Locations (1 sites)
Ainshams University Hospitals, Cairo, Abbasiya 1181 Egypt
Eligibility Criteria
Inclusion Criteria: * Female patients older than 21 years old * American Society of Anesthesiologists (ASA) physical status II. Exclusion Criteria: * Known allergy to one of the study\'s medications. * Skin infections at the site of the needle puncture. * Significant organ dysfunction (hepatic, renal, or cardiac dysfunction), coagulopathy or recent anticoagulant use, epilepsy. * Patients diagnosed with obstructive sleep apnoea, pulmonary compromise .
Conditions Radiation Pneumonitis
Phase NA
Enrollment 380
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Radiotherapy is one of the important treatments to improve the survival rate of breast cancer patients, but also has the risk of radiation lung injury, which can develop into pulmonary fibrosis. Hyperbaric oxygen can improve the tissue after radiation by promoting the function of vascular endothelial cells and fibroblasts, and reducing the secretion of inflammatory factors, thereby inhibiting the process of fibrosis and fiber atrophy after radiotherapy, and promoting tissue repair. Therefore, it has the potential value of treating chronic radiation injury. We aim to investigate whether hyperbaric oxygen treatment can reduce the incidence of radiation pneumonia and improve patients' quality of life, and to evaluate its safety and the impact on the patients' long-term survival outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: hyperbaric oxygen therapy — hyperbaric oxygen therapy

Primary Outcomes

  • Incidence of radiation pneumonitis (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-03-01
Completion: 2026-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 380 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangdong Provincial People's Hospital
Collaborators: First Affiliated Hospital, Sun Yat-Sen University
Contact Information
Study Contact:
Kun Wang
13922118086
gzwangkun@126.com
Kun Wang
13922118086
gawangkun@126.com
Guangdong Provincial People's Hospital
Interventions
  • Behavioral: hyperbaric oxygen therapy — hyperbaric oxygen therapy
Study Locations (1 sites)
Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080 China
Eligibility Criteria
Inclusion Criteria: * (1) Volunteer to participate and sign informed consent in writing. (2) Past pathological diagnosis of breast cancer followed by radical treatment/surgery for breast cancer, followed by adjuvant chemotherapy followed by radiotherapy. (3) Excluding patients with simple neck lymph node recurrence and patients with distant metastases. (4) There is no secondary malignant tumor in other parts. (5) Age at entry ≥ 18 years old and ≤ 70 years old, both male and female. (6) The Eastern Cooperative Oncology Group (ECOG) has a performance status score of 0 or 1. (7) The expected survival period is ≥2 years. (8) There was no acute radiation lung injury in chest CT examination before and after radiotherapy Exclusion Criteria: * (1) Contraindications to hyperbaric oxygen therapy: lung disease (severe chronic obstructive airway disease, bullous lung disease, acute or chronic lung infection, uncontrolled asthma, untreated pneumothorax), in the past History of ear surgery, middle ear disease (eustachian tube dysfunction, recurrent dizziness), eye disease (retinal detachment). (2) Have received hyperbaric oxygen therapy in the past. (3) Radiation pneumonia had occurred at the time of enrollment or before receiving hyperbaric oxygen therapy. (4) Women who are pregnant or breastfeeding. (5) Patients who have not completed comprehensive breast cancer treatment due to disease progression, intolerable side effects, abandonment of treatment and other reasons. (8) Patients who need mechanical ventilation support. (9) Patients who cannot follow and understand simple commands. (10) Patients with disorientation and mental disorders.
Conditions Breast Cancer, Locally Advanced or Metas...
Phase PHASE1
Enrollment 348
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

In phase Ia study, the safety and tolerability of BL-B07D1 in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M07D1. In phase Ib study, the safety and tolerability of BL-M07D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-M07D1 in patients

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BL-M07D1 — Administration by intravenous infusion

Primary Outcomes

  • Phase Ia: Dose limiting toxicity (DLT) (Up to 21 days after the first dose)
  • Phase Ia: Maximum tolerated dose (MTD) (Up to 21 days after the first dose)
  • Phase Ib: Phase II clinical study recommended dose (RP2D) (Up to 21 days after the first dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2022-08-09
Completion: 2027-12
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 348 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Principal Investigators:
  • Erwei Song, PHD (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
  • Herui Yao, PHD (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Contact Information
Study Contact:
Sa Xiao, PHD
+86-15013238943
xiaosa@baili-pharm.com
Rongbo Lin
Fujian Cancer Hospital
Jun Jia
Dongguan People's Hospital
Interventions
  • Drug: BL-M07D1 — Administration by intravenous infusion
Study Locations (7 sites)
Fujian Cancer Hospital, Fuzhou, Fujian China
Dongguan People's Hospital, Dongguan, Guangdong China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, Guangzhou 510120 China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan China
Zhongnan Hospital of Wuhan University, Wuhan, Hubei China
Jinan Central Hospital, Jinan, Shandong China
Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, Zhejiang China
Eligibility Criteria
Inclusion Criteria: * 1\. Sign the informed consent voluntarily and follow the program requirements * 2\. No gender limitation; * 3\. Age: ≥18 years old and ≤75 years old (Stage Ia);≥18 years old (Ib); * 4\. Expected survival time ≥3 months; * 5\. Inoperable locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors that have been histopathologically and/or cytologically confirmed and have failed standard therapy, or are not available for standard therapy, or are not currently eligible for standard therapy; HER2 positive: IHC3+, or IHC2+ and ISH positive; HER2 low expression: IHC2+ and ISH negative, or IHC1+; * 6\. Agree to provide archived tumor tissue samples or fresh tissue samples from the primary tumor or metastatic tumor within 2 years (to detect the expression of HER2 protein in tumor pathological tissue and explore the correlation between HER2 protein and bl-M07D1 validity index); If subjects are unable to provide tumor tissue samples, they will be admitted after evaluation by the investigator if other admission criteria are met. * 7\. Must have at least one measurable lesion as defined by RECIST V1.1; * 8\. ECOG score of 0 or 1; * 9\. Toxicity of previous antitumor therapy has returned to level ≤1 as defined by NCI-CTCAE V5.0 (the investigator considered asymptomatic laboratory abnormalities, such as elevated ALP, hyperuricemia, and elevated blood glucose, etc.); Except for toxicity that the investigator judged to have no safety risk, such as alopecia, pigmentation, grade 2 peripheral neurotoxicity, etc.); * 10\. No serious cardiac dysfunction, left ventricular ejection fraction ≥50%; * 11\. Organ function level must meet the following requirements and meet the following standards: A) Bone marrow function: absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelet count ≥90×10\^9/L, hemoglobin ≥90 g/L; B) Liver function: total bilirubin (TBIL≤1.5 ULN), AST and ALT ≤2.5 ULN in patients without liver metastasis, AST and ALT ≤5.0 ULN in patients with liver metastasis; C) Renal function: creatinine (Cr) ≤1.5 ULN, or creatinine clearance (Ccr) ≥50 mL/min (according to the Cockcroft and Gault formula). * 12\. Coagulation function: International standardized ratio (INR) ≤1.5, and activated partial thrombin time (APTT) ≤1.5ULN; * 13\. Urinary protein ≤2+ or ≤1000mg/24h; * 14\. For premenopausal women at risk of fertility, pregnancy tests must be performed within 7 days prior to the start of treatment. Serum/urine pregnancy must be negative and must be non-lactation; All enrolled patients (male and female) should use adequate barrier contraception throughout the treatment cycle and 6 months after the end of treatment Exclusion Criteria: * 1\. Prior use of chemotherapy, biotherapy, immunotherapy, radical radiotherapy, major surgery (as defined by the investigator), targeted therapy (including small molecule tyrosine kinase inhibitors) and other antitumor therapies within 4 weeks or 5 half-lives (whichever is less) prior to initial dosing; Mitomycin and nitrosourea were administered within 6 weeks prior to initial administration; For oral fluorouracil drugs such as gio, capecitabine, or palliative radiotherapy within 2 weeks before initial administration; The Chinese medicine with anti-tumor indication was given within 2 weeks before the first administration. * 2\. Prior ADC treatment (phase Ib only) with the toxin of camptothecin derivatives (topoisomerase I inhibitors); * 3\. History of severe heart disease, such as symptomatic congestive heart failure (CHF) grade 2 or greater (CTCAE 5.0), NYHA grade 2 or greater heart failure, history of transmural myocardial infarction, unstable angina, etc.; * 4\. QT prolongation (male QTc \> 450 msec or female QTc \> 470 msec), complete left bundle branch block, III atrioventricular block; * 5\. Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, systemic treatment of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and hashimoto's thyroiditis, etc., with the exception of type I diabetes, only replacement therapy can control the hypothyroidism, no systemic treatment of skin disease (e.g., vitiligo, psoriasis); * 6\. Other malignancies diagnosed within 5 years prior to first administration, except for radical basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radical resected carcinoma in situ; * 7\. Screening for unstable thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism requiring therapeutic intervention within the first 6 months; Infusion device-related thrombosis is excluded; * 8\. Patients with poorly controlled pleural effusion with clinical symptoms were judged by researchers to be unsuitable for inclusion; * 9\. Hypertension poorly controlled by medications (systolic \& GT; 150 mmHg or diastolic pressure \& GT; 100 mmHg); * 10\. According to CTCAE V5.0, patients were defined as ≥3 grade of lung disease, ≥2 grade of radioactive lung disease, existing or with a history of ILD; * 11\. Symptoms of active CNS metastasis. But the researchers concluded that patients with stable parenchymal metastases could be included. The definition of stability must meet the following four requirements: A. Seizureless state lasting \> 12 weeks with or without antiepileptic drugs; B. Glucocorticoids are not required; C. Two consecutive MRI scans (at least 4 weeks between scans) showed stable imaging state; D. Asymptomatic patients have been stable for more than 1 month after treatment; * 12\. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipient component of BL-M07D1; * 13\. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (ALLO-HSCT); * 14\. Equivalent cumulative dose of doxorubicin in anthracycline adjuvant therapy was \> 360 mg/m\^2; * 15\. Positive human immunodeficiency virus antibody (HIVAb), active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number \> lower limit) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA \> lower limit); * 16\. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc. * 17\. Participated in another clinical trial within 4 weeks prior to initial administration (starting from the time of last administration); * 18\. Pregnant or nursing women; * 19\. Other conditions considered inappropriate for participation in this clinical trial by the investigator
Conditions Breast Cancer, Colon Cancer, Head and Ne...
Phase NA
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

Cancer can be a very traumatic experience for the people affected and the majority of the psychological literature focuses on this. Less proliferated and researched is the increasingly recognized fact that as a result of struggling with such traumatic adversities, some people experience what is known as post-traumatic growth (PTG). PTG not only allows them to overcome their trauma (e.g., impact of cancer) and return to pre-diagnosis functioning (e.g., health, wellbeing, employment) but also results in them going over and above their previous state (e.g., increased resilience). This renders PTG an important phenomenon that could be enhanced as part of the support people with cancer receive. IC-Growth has two interconnected paths, namely a research one and another of health policy and best practice recommendations. On the first path, is a sequence of three studies, starting with a systematic review, followed by a cross-sectional study and concludes with a randomized control trial (RCT). The systematic review and close collaboration with experts (e.g., patient associations) will lead to the development of a novel manual to facilitate PTG in groups of people with cancer. The cross-sectional study will explore relationships between variables (e.g., PTG, quality of life, biological variables, illness perceptions, distress, anxiety, depression) in people with cancer (n = 150-180). Lastly, the RCT will evaluate the intervention's effects among three different groups (breast, colorectal, and head and neck cancers, n = 50-60 per group). On the other path, is the development of health policy and best practice recommendations regarding the psychosocial support of people with cancer in Greece. The project's results will be disseminated to stakeholders who provide support to people with cancer (e.g., oncologists, surgeons, psychologists, psychiatrists), through professional associations, a conference on "Psychosocial Support in Oncology", and publications in scientific journals. Overall, IC-Growth is a multidisciplinary project (i.e., psychology, medical, patient organizations, health policy) and joins the clinical, research and policy fields together to workable actions leading to empowering the wider community of people with cancer and improving their care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: IC-Growth ACT-Based Support Program — IC-Growth Psychosocial Group Intervention is a structured, manualized program designed to enhance post-traumatic growth (PTG) in adults diagnosed with breast, colorectal, or head and neck cancer. The intervention is delivered in small groups (8-10 participants) over 6-8 weeks, with weekly 90-minute sessions led by trained health psychologists. The program integrates evidence-based therapeutic approaches, including Acceptance and Commitment Therapy (ACT), mindfulness, cognitive restructuring, narrative exercises, and interpersonal support-building, with the goal of improving psychological flexibility, resilience, quality of life, and overall well-being.

Primary Outcomes

  • Post-Traumatic Growth (PTG) (Baseline and post-intervention (6-8 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-01
Completion: 2025-12-30
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre for Research and Technology Hellas
Collaborators: AHEPA University Hospital, Hellenic Cancer Society, Theagenio Cancer Hospital
Contact Information
Study Contact:
Christina Karamanidou, Psychology, PhD
+306949576105
ckaramanidou@certh.gr
AHEPA University Hospital
Interventions
  • Behavioral: IC-Growth ACT-Based Support Program — IC-Growth Psychosocial Group Intervention is a structured, manualized program designed to enhance post-traumatic growth (PTG) in adults diagnosed with breast, colorectal, or head and neck cancer. The intervention is delivered in small groups (8-10 participants) over 6-8 weeks, with weekly 90-minute sessions led by trained health psychologists. The program integrates evidence-based therapeutic approaches, including Acceptance and Commitment Therapy (ACT), mindfulness, cognitive restructuring, narrative exercises, and interpersonal support-building, with the goal of improving psychological flexibility, resilience, quality of life, and overall well-being.
Study Locations (1 sites)
AHEPA University Hospital, Thessaloniki, 54636 Greece
Eligibility Criteria
Inclusion Criteria: 1. Adults (≥ 18 years) 2. Having a diagnosis of a. Breast Cancer, b. Colorectal Cancer, or c. Head and Neck Cancer. 3. Having concluded the planned chemotherapy courses and related hospital admissions 4. Having no more than 5 years since the initial diagnosis. Exclusion Criteria: 1. Being in active psychological or psychiatric treatment 2. Having an unmanaged mental health difficulty 3. Having a severe cognitive impairment 4. Being unable to give informed consent 5. Being unable to speak or read Greek 6. Having one or more relapses 7. Diagnosed with another type of cancer within 5 years prior to recruitment. 8. Having less than one-year life expectancy
Conditions Breast Tumors, Wound Healing, Collagen W...
Phase NA
Enrollment 60
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the safety of the collagen wound dressing (HealiAid) in breast tumor patients with surgical treatment. The main questions it aims to answer are: 1. To record the incidence of the postoperative complications and adverse events (AEs) after applying the HealiAid wound dressing in patients undergoing surgery for breast tumor. 2. To evaluate the patients' satisfaction and quality of life using the Breast Q questionnaire before surgery and at weeks 2, 12, 26, and 52 after the surgery. 3. To evaluate the patients' results of vital signs, hematology tests, tumor marker tests, breast ultrasonography, and mammography after the surgery. Participants will undergo a breast surgery. Within the surgery procedure, the tumor will be completely removed with a margin of 1-2 cm surrounding healthy tissue and the wounds will be cleaned properly before the patients receive the HealiAid Collagen Wound Dressing at treatment visit, and six follow up visits at week 1, 2, 4, 12, 26 and 52.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: HealiAid Collagen Wound Dressing — Within the surgery procedure, the tumor is completely removed and the wounds are cleaned properly before applying the HealiAid Collagen Wound Dressing. HealiAid is soft and pliable. It can be adjusted to the size of the wound, and it is recommended to apply one to four pieces per wound. HealiAid Collagen Wound Dressing will be kept in place until absorbed completely.

Primary Outcomes

  • Incidence of the postoperative complications and adverse events (Day0 through out 52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-20
Completion: 2027-05-31
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maxigen Biotech Inc.
Contact Information
Study Contact:
Attending Physician
+886952655107
corn110006@gmail.com
Cardinal Tien Hospital
Attending Physician
+886970405127
hungcs@tmu.edu.tw
Taipei Medical University Hospital
Attending Physician
+886287923311
liaogs20371@gmail.com
Tri-Service General Hospital
Interventions
  • Device: HealiAid Collagen Wound Dressing — Within the surgery procedure, the tumor is completely removed and the wounds are cleaned properly before applying the HealiAid Collagen Wound Dressing. HealiAid is soft and pliable. It can be adjusted to the size of the wound, and it is recommended to apply one to four pieces per wound. HealiAid Collagen Wound Dressing will be kept in place until absorbed completely.
Study Locations (3 sites)
Cardinal Tien Hospital, New Taipei City, Taiwan 23148 Taiwan
Taipei Medical University Hospital, Taipei, Taiwan 110301 Taiwan
Tri-Service General Hospital, Taipei, Taiwan 114202 Taiwan
Eligibility Criteria
Inclusion Criteria: * Age 18-70 years old. * Patients are diagnosed with a benign or malignant breast tumor, that tumor size of ≦ 5 cm and no distant metastasis assessed by the imaging (breast ultrasonography, mammography, or MRI) and pathologic examination within 12 weeks before screening. If a benign breast tumor is identified through imaging and subsequently removed via surgery performed after the subject's enrollment in the study, the pathology report from that surgery should be used instead of any previous report. * Patients diagnosed with a breast tumor, or those with a history of radiation and chemotherapy, who are scheduled to undergo surgery such as partial mastectomy, breast-conserving surgery, sentinel lymph node dissection, and/or axillary lymph node dissection . * Patients who understand and are able to comply with follow-up visits and treatment during the trial period. * Patients who are willing and capable of providing written informed consent. Not a person subject to a sentence of guardianship or subject to judicial guardians. Exclusion Criteria: * Patients with breast cancer stage III or IV. * Patients with inflammatory breast cancer. * Patients with multicentric lesions or lesions with diffuse microcalcification. * Patients with retro areolar breast carcinoma. * Have a history of severe allergies or are allergic to collagen. * Collagen vascular disease. * History of serious postoperative complications. * Infected wound. * Patients who require emergency surgery. * Patients with coagulation dysfunction, such as abnormal preoperative coagulation time (prothrombin time (PT)\>18 seconds or partial thromboplastin time (PTT) \>50 seconds) * Patients with untreated or unstable diabetes, that the fasting blood sugar \>180 mg/dL or postprandial blood sugar \>200 mg/dL. * Patients with untreated or unstable chronic diseases, such as hypertension, hyperlipidemia, cardiovascular disease, stroke. * Patients with Body mass index (BMI) \> 30. * Patients who are pregnant or breastfeeding women. * Patients with drug abuse or addiction. * Others who have been judged by the principal investigator as participating in this trial will endanger their physical and mental health.
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase PHASE2
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial studies the effect of avapritinib in treating malignant solid tumors that have a genetic change (mutation) in CKIT or PDGFRA and have spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Avapritinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Avapritinib may help to control the growth of malignant solid tumors.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Avapritinib — Given PO

Primary Outcomes

  • Overall response rate (ORR) (or date of death from any cause, whichever came first, assessed up to 50 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-01-20
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Jordi Rodon Ahnert (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Jordi R Rodon, MD, PHD
(713) 792-5603
jrodon@mdanderson.org
Jordi Rodon Ahnert
713-563-1930
jrodon@mdanderson.org
M D Anderson Cancer Center
Jordi Rodon Ahnert
M D Anderson Cancer Center
Interventions
  • Drug: Avapritinib — Given PO
Study Locations (1 sites)
M D Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: 1. The patient (or legally acceptable representative if applicable) provides written informed consent for the study. 2. Male or female ≥18 years of age on the day of informed consent signing. Adolescent patients aged 12 years and older are allowed with signed assent and parental consent according to institutional guidelines and requirements. 3. Cohorts 1 and 2: Patient has a locally advanced or metastatic solid tumor and has progressed on appropriate standard therapy, has not shown clinically meaningful benefit to appropriate standard therapy, has no available standard therapy, or has declined appropriate standard therapy. • NOTE: Specific solid tumor types include but are not limited to melanoma, breast cancer, lung cancer, gastroesophageal cancer, colorectal cancer, sarcoma, solid tumors NOS, and primary CNS tumors. Patients with any other recurrent solid tumor type with the exception of gastrointestinal stromal tumor (GIST) will be eligible. 4. Cohort 3: Patient has newly diagnosed IDH wild-type, MGMT-unmethylated glioblastoma. Patients must have received prior treatment with radiation and concurrent temozolomide per standard of care.27 Patients must have completed radiation and concurrent temozolomide 3-8 weeks prior to study treatment initiation. 5. Measurable disease per the RECIST v1.1 or RANO criteria, as appropriate, for Cohorts 1 and 2. Patients in Cohort 3 can have measurable or non-measurable disease per the RANO criteria. 6 Documented pathogenic CKIT activating mutation (Cohort 1) OR pathogenic PDGFRA activating mutation (Cohort 2) based on Clinical Laboratory Improvement Amendments-certified next-generation sequencing diagnostic test. Cohort 3 should have pathogenic CKIT or PDGFRA activating mutation/amplification based on CLIA-certified NGS diagnostic test. CKIT and PDGFRA mutation pathogenicity will be verified by the MD Anderson Cancer Center's Precision Oncology Decision Support team. Acceptable CKIT/PDGFRA mutations for study eligibility are listed in Appendix E. 7\. Has available archival tissue for CKIT/PDGFRA mutation (amplification \[Cohort 3 only\]) retrospective testing. 8\. Adequate organ and marrow function as defined below within 7 days of study treatment initiation: * White blood cell count \>2,500/µL and \<15,000/µL * Absolute neutrophil count ≥1.5 × 109/L (without granulocyte colony-stimulating factor support within 2 weeks of laboratory test used to determine eligibility) * Platelet count ≥75 × 109/L (without transfusion within 2 weeks of laboratory test used to determine eligibility) * Hemoglobin ≥9.0 g/dL (without blood transfusion within 7 days of laboratory test used to determine eligibility) * Total bilirubin ≤1.5 × upper limit of normal (ULN); if hepatic metastases are present, ≤3.0 × ULN * Aspartate transaminase and alanine transaminase ≤2.5 × ULN; if hepatic metastases are present, ≤5.0 × ULN * Serum creatinine ≤2.0 × ULN or creatinine clearance ≥45 mL/min. 9. Cardiac ejection fraction \>45% per screening echocardiogram or multigated acquisition scan. 10\. Eastern Cooperative Oncology Group performance status of 0-2. 11\. Life expectancy ≥3 months. 12\. Willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations. 13\. Willing to undergo biopsy as required by the study. 14\. Females must be postmenopausal (defined as ≥45 years of age with at least 12 months of spontaneous amenorrhea) or premenopausal with documented surgical sterilization (tubal ligation, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or evidence of non-childbearing status for women of childbearing potential (negative serum beta-human chorionic gonadotropin pregnancy test) within 3 days of study treatment initiation. 15\. Females of childbearing potential must either abstain from heterosexual intercourse or use a highly effective method of contraception for the course of the study and for 6 weeks after the last dose of study treatment. 16\. Males with female partners of reproductive potential must either abstain from sexual intercourse or they and their partners must use a highly effective method of contraception when engaging in sexual intercourse for the course of the study through 30 days after the last dose of study treatment. Exclusion Criteria: Patients eligible for this study must not meet any of the following criteria: 1. Patients who have GIST. 2. Patients with tyrosine kinase inhibitor-resistant CKIT mutation V654A or T670I. 3. Patients with meningeal carcinomatosis, leptomeningeal carcinomatosis, spinal cord compression, or symptomatic or unstable brain metastases. Note: Patients with stable brain metastases (defined as asymptomatic or no requirement for high-dose or increasing dose of systemic corticosteroids) and without imminent need of radiation therapy) are eligible (including those with untreated brain metastases). If applicable, patients must have completed brain radiation therapy and recovered adequately from any associated toxicity and/or complications prior to eligibility assessment. For patients who have received prior radiation therapy, post-treatment magnetic resonance imaging scan should show no increase in brain lesion size/volume. 4. History of documented congestive heart failure (New York Heart Association functional classification III-IV) or serious cardiac arrhythmias requiring treatment. 5. QT interval corrected using Fridericia's formula of \>470 msec. 6. Is currently participating or has participated in a study of an investigational agent or has used an investigational device within 2 weeks prior to study treatment initiation. 7. Prior anticancer chemotherapy, hormone therapy, immunotherapy, targeted therapy, radiation therapy, or surgery within 2 weeks prior to study treatment initiation. * NOTE: Patients must have recovered from all AEs due to previous therapies to ≤ Grade 1 or baseline (except alopecia). Patients with ≤ Grade 2 neuropathy are eligible. * NOTE: If patient received major surgery, she/he must have recovered adequately from the toxicity and/or complications from the intervention prior to study treatment initiation. * NOTE: Patients in Cohort 3 must have completed radiation and concurrent temozolomide 3-8 weeks prior to study treatment initiation. 8. Symptomatic non-healing wound, ulcer, gastrointestinal perforation, or bone fracture. 9. History of psychotic or depressive disorder. Patients whose disorder is well controlled on a stable antipsychotic or antidepressant medication for at least 12 months prior to study entry will be eligible. 10. Concomitant use of a known strong cytochrome P450 (CYP)3A4 inhibitor or strong CYP3A4 inducer. The required washout period prior to study treatment initiation is 2 weeks or 5 half-lives, whichever is shortest. 11. Females who are pregnant or breastfeeding. 12. Unable to swallow and retain oral medications. 13. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study treatment (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). 14. Known additional malignancy that is progressing or requires active treatment. NOTE: Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical cancer in situ that have undergone potentially curative therapy are not excluded. 15. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the investigator. 16. Prior treatment with an intracerebral agent or bevacizumab (Cohort 3 only). 17. Prior treatment including radiation, chemotherapy, or immunotherapy for low-grade glioma (Cohort 3 o
Conditions Breast Cancer, Cancer
Phase NA
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, controlled study to assess the effect of Sidekick Health's digital program on self-efficacy and medication adherence in breast cancer patients prescribed adjuvant anti-hormonal treatment. Participants will be treated with the digital program in addition to standard of care (SoC), or SoC only.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Device: Sidekick digital patient support program for patients with breast cancer — A digital health program delivered through an app that provides holistic lifestyle intervention and medication adherence support.
  • Other: Standard of care for breast cancer patients — Standard of care includes adjuvant breast cancer treatment and optional cancer rehabilitation

Primary Outcomes

  • Self-efficacy and health education impact (12 weeks from baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-05-31
Completion: 2026-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sidekick Health
Collaborators: Landspitali University Hospital, University of Iceland, Icelandic Research Center
Principal Investigators:
  • Olof Kristjana Bjarnadottir, MD, PhD (PRINCIPAL_INVESTIGATOR) - Landspitali University Hospital
Contact Information
Study Contact:
Sigridur Lara Gudmundsdottir, PhD
+3546114475
siggalara@sidekickhealth.com
Soley Dilja Stefansdottir, Nurse
+3546218594
rannsoknskh@landspitali.is
Landspitali University Hospital
Interventions
  • Device: Sidekick digital patient support program for patients with breast cancer — A digital health program delivered through an app that provides holistic lifestyle intervention and medication adherence support.
  • Other: Standard of care for breast cancer patients — Standard of care includes adjuvant breast cancer treatment and optional cancer rehabilitation
Study Locations (1 sites)
Landspitali University Hospital, Reykjavik, 101 Iceland
Eligibility Criteria
Inclusion Criteria: * Adult patient (18 years or older) diagnosed with breast cancer of stage I, II or III from 1st September 2023 or later * Have been prescribed adjuvant endocrine therapy for breast cancer. * Understands written and spoken Icelandic or English. * Owns a smart-phone compatible with the Sidekick app and capable to use it * Willing to download the Sidekick app on the smart-phone and to comply with the study measures and visits according to the protocol. * Capable of providing informed consent for participating in the study. Exclusion Criteria: * Having other concurrent conditions that in the opinion of the oncologist may compromise patient safety or study objectives. * Concurrent participation in another clinical study in which the study treatment may confound the evaluation of the investigational program. * Metastatic breast cancer (stage IV) * Previous experience with Sidekick breast cancer program
Conditions Breast Cancer, Tumor, Breast
Phase PHASE2
Enrollment 55
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The standard treatment for participants whose cancer has returned after breast conserving surgery is radiation given twice daily (separated by at least 6 hours) for a total of 30 treatments. The purpose of this study is to find out if giving radiation once a day for 15 treatments after repeat breast conserving surgery works as well as giving it the standard way.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Radiation Therapy — Weeks 1, 2 and 3 * Weeks 1, 2 and 3 will include 5 days of treatment. * One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes.

Primary Outcomes

  • Treatment-related adverse events as graded by CTCAE criteria (1 year from the completion of re-irradiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-11-30
Completion: 2029-08-09
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Case Comprehensive Cancer Center
Principal Investigators:
  • Janice Lyons, MD (PRINCIPAL_INVESTIGATOR) - University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
  • Rahul Tendulkar, MD (PRINCIPAL_INVESTIGATOR) - Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Contact Information
Study Contact:
Janice Lyons, MD
(216) 844-2514
Janice.lyons@uhhospitals.org
Rahul Tendulkar, MD
866-223-8100
TaussigResearch@ccf.org
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
Rahul Tendulkar, MD
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
Interventions
  • Radiation: Radiation Therapy — Weeks 1, 2 and 3 * Weeks 1, 2 and 3 will include 5 days of treatment. * One radiation treatment to breast on each of the 5 days. Each radiation treatment session will last a 30 minutes.
Study Locations (2 sites)
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio 44106-5065 United States
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio 44195 United States
Eligibility Criteria
Inclusion Criteria: * Participants' recurrences must have histologically confirmed ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), tubular or mixed histologies. Three years of time must have elapsed since the end of the last course of whole breast irradiation. * Lesion size \< 3 cm treated with a partial mastectomy. Participants with invasive cancer and clinically and radiographically negative axillas do not require an axillary lymph node sampling unless they did not have prior axillary lymph node sampling (e.g. previous cancer was DCIS). Participants with DCIS as their recurrence do not require surgical assessment of the axilla. Repeat sentinel lymph node biopsy is permitted. * Negative resection margins with at least no tumor on ink or a negative re-excision. * Participants with invasive recurrence must have a negative re-staging work-up consisting of either a CT chest/abdomen and a bone scan or a PET scan. * Hormonal therapy is allowed. If chemotherapy is planned, it can be delivered either prior to or after the radiation is delivered. There must be at least 2 weeks between radiation and chemotherapy. HER2 directed therapy can be delivered concurrently with radiation. * Participants must be \> 18 years of age. Because no dosing or adverse event data are currently available on the use of breast re-irradiation in participants ≤18 years of age, children are excluded from this study. * Participants must have the ability to understand and the willingness to sign a written informed consent document. * Performance status: ECOG Performance status ≤ 2. * Life expectancy of ≥ 12months, in the opinion of and as documented by the investigator. * Not based on gender; this trial is open to any gender, defined as self-representation of gender identity. Exclusion Criteria: * Participants with nodal or distant metastatic disease \< 3 years since prior radiation. * Participants with invasive pure lobular carcinoma, extensive lobular carcinoma in-situ, extensive ductal carcinoma in-situ (spanning more than 3 cm), or uncontrolled nonepithelial breast malignancies such as lymphoma or sarcoma. * Participants with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm). Palpable or radiographically suspicious contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular, or internal mammary lymph nodes unless these are histologically or cytologically confirmed negative. * Participants with Paget's disease of the nipple. * Participants with skin involvement. * Participants with scleroderma or dermatomyositis. * Participants with psychiatric, neurologic, or addictive disorders that would preclude obtaining informed consent. * Participants who are pregnant or lactating due to potential fetal exposure to radiation and unknown effects of radiation on lactating females. * Participants with known BRCA 1/BRCA 2 mutations.
Conditions Metastatic Breast Cancer
Phase PHASE3
Enrollment 600
Locations 224 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Lasofoxifene in combination with abemaciclib — 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
  • Drug: Fulvestrant in combination with abemaciclib — Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day

Primary Outcomes

  • Progression free survival (PFS) (Within approximately 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-10-31
Completion: 2028-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: LeonaBio
Contact Information
Study Contact:
Simon Daggett - Senior Vice President, Clinical Operations
(909) 374-3793
clinicaltrials@leonabio.com
Clinical Trials Office - All Mayo Clinic Locations
855-776-0015
Mayo Clinic - Scottsdale
Carissa Ganzer
carissamague@arizona.edu
University of Arizona - Cancer Center
Interventions
  • Drug: Lasofoxifene in combination with abemaciclib — 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day
  • Drug: Fulvestrant in combination with abemaciclib — Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day
Study Locations (224 sites)
Mayo Clinic - Scottsdale, Scottsdale, Arizona 85259 United States
University of Arizona - Cancer Center, Tucson, Arizona 85719 United States
Providence Medical Foundation - Santa Rosa, CA, Santa Rosa, California 95403 United States
Mayo Clinic - Jacksonville, Jacksonville, Florida 32224 United States
Miami Cancer Institute, Miami, Florida 33143 United States
Miami Cancer Institute Plantation, Plantation, Florida 33324 United States
Emory University School of Medicine, Atlanta, Georgia 30322 United States
Norton Cancer Institute, Louisville, Kentucky 40202 United States
Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland 21231 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: 1. Pre- or postmenopausal women or men. 2. Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease. 3. Histological or cytological confirmation of ER+/HER2 - disease 4. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer. 5. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue. 6. Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions. 7. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy. 8. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 9. Adequate organ function 10. Able to swallow tablets 11. Brain metastases are allowed only if the following 4 parameters hold: 1. Asymptomatic, 2. Definitively treated (e.g., radiotherapy, surgery), 3. Not requiring steroids up to 4 weeks before study treatment initiation, AND 4. Central nervous system disease stable for \>3 months prior to registration as documented by magnetic resonance imagining (MRI). 12. Able to understand and voluntarily sign a written informed consent before any screening procedures. 13. Every attempt should be made to obtain a biopsy of metastatic breast cancer tissue, when safe and feasible, to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to American Society of Clinical Oncology/College of American Pathologists guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is done, it may undergo genomic testing at some point to assess for ESR1 mutations and correlation with ctDNA results. If a biopsy is not possible or inappropriate from a clinical standpoint, the ER and HER2 status from the subject's most recent biopsy must confirm that the subject is ER+ and HER2 Exclusion Criteria: 1. Lymphangitic carcinomatosis involving the lung. 2. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy. 3. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator. 4. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy. 5. Subjects with a known hypersensitivity to fulvestrant or to any of the excipients 6. Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1). 7. Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.) 8. History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of \>480 msec. 9. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto). 10. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure \[CHF\] or prolonged immobilization). 11. On concomitant strong CYP3A4 inhibitors. 12. On strong and moderate CYP3A4 inducers. 13. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption. 14. Active systemic bacterial or fungal infection (requiring intravenous \[IV\] antibiotics or antifungals at the time of initiating study treatment). 15. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). 16. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery. 17. Positive serum pregnancy test (only if premenopausal). 18. Sexually active premenopausal women and men unwilling to use double-barrier contraception. 19. Women who are breast feeding 20. History of non-compliance to medical regimens. 21. Unwilling or unable to comply with the protocol. 22. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days. 23. Subjects with a history of familial hypertriglyceridemia or fasting triglyceride levels \>880 mg/dL at screening. 24. Fasting triglyceride level \>300 mg/dL and ≤880 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting triglyceride level less than or equal to 300 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment). 25. Fasting cholesterol level \>400 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting cholesterol level less than or equal to 400 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
Conditions Anatomic Stage IV Breast Cancer AJCC v8,...
Phase PHASE4
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography \[PET\]/magnetic resonance imaging \[MRI\]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain metastasis). Diagnostic procedures, such as 64Cu-DOTA-trastuzumab PET/MRI, may help find HER2+ breast cancer that has spread to the brain and determine whether cancer in the brain takes up trastuzumab, which may predict for response to trastuzumab deruxtecan (the standard of care chemotherapy).

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Other: Copper Cu 64-DOTA-Trastuzumab — Given IV
  • Procedure: Magnetic Resonance Imaging — Undergo PET/MRI
  • Device: Positron Emission Tomography — Undergo PET/MRI
  • Biological: Trastuzumab — Given IV
  • Biological: Trastuzumab Deruxtecan — Given IV

Primary Outcomes

  • Percent of patients with quantifiable 64Cu-DOTA-trastuzumab PET uptake (Until disease progression or death, up to 5 years.)
  • Comparison of average min SUVmax values in responders versus non-responders. (Until disease progression or death, up to 5 years.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-12-21
Completion: 2027-04-27
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Joanne E Mortimer (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
Joanne E. Mortimer
626-256-4673
jmortimer@coh.org
City of Hope Medical Center
Joanne E. Mortimer
City of Hope Medical Center
Interventions
  • Other: Copper Cu 64-DOTA-Trastuzumab — Given IV
  • Procedure: Magnetic Resonance Imaging — Undergo PET/MRI
  • Device: Positron Emission Tomography — Undergo PET/MRI
  • Biological: Trastuzumab — Given IV
  • Biological: Trastuzumab Deruxtecan — Given IV
Study Locations (1 sites)
City of Hope Medical Center, Duarte, California 91010 United States
Eligibility Criteria
Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Women with documented metastatic HER2 positive breast cancer (American Society of Clinical Oncology \[ASCO\] College of American Pathologist \[CAP\] guidelines) who have brain metastases * Age \> 18 years * Eastern Cooperative Oncology Group (ECOG) 0-2 * Patients with leptomeningeal disease will be considered eligible * Planned therapy with fam-trastuzumab deruxtecan * Left ventricular ejection fraction (LVEF) \> 50% * Absolute neutrophil count (ANC) \> 1.5 x 10\^9/L * Platelets \> 100 x 10\^9/L * Hemoglobin \> 9 g/dL * Total (T.) bilirubin \< 3 x upper limit of normal (ULN) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 5 x ULN * Creatinine clearance \> 30 ml/min (by Cockcroft-Gault formula) * Activated partial thromboplastin time (aPTT) \< 1.5 x ULN * Prior therapy for central nervous system (CNS) disease is allowed, but at least 1 lesion \> 1.5 cm is evident on MRI Exclusion Criteria: * Need for immediate local intervention for brain metastases * Noninfectious interstitial lung disease or pneumonitis requiring glucocorticoids * Clinically significant corneal disease * Myocardial infarction \< 6 months before, congestive heart failure (CHF), unstable angina, or serious cardiac arrhythmia
Conditions Metastatic Cancer, Metastatic Breast Can...
Phase PHASE1
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-13
Study Details Design, interventions, and primary outcomes

About This Study

SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SV-101 — SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

Primary Outcomes

  • Antitumor activity (4-6 weeks after each treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-02-01
Completion: 2025-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Williams Cancer Foundation
Collaborators: Syncromune, Inc.
Principal Investigators:
  • Jason Williams, MD (PRINCIPAL_INVESTIGATOR) - Williams Cancer Institute
Contact Information
Study Contact:
Jason Williams, MD
(954) 530-4606
dr@williamscancerinstitute.com
Eduardo Cortés
+52 55 5507 9739
eduardo@cancerimmunebio.com
Jason Williams, MD
1-954-530-4606
dr@williamscancerinstitute.com
Hospital Diomed
Interventions
  • Drug: SV-101 — SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
Study Locations (1 sites)
Hospital Diomed, Mexico City, 11810 Mexico
Eligibility Criteria
Inclusion Criteria: 1. Male or female, aged \>18 years old at the time of signed informed consent 2. Provide written informed consent and must be willing to adhere with treatment and follow-up. 3. Subjects with advanced and/or metastatic histologically or cytologically confirmed solid tumor who have not responded or progressed after standard therapies or for whom no further standard therapy exists or standard therapy is not available. 4. Meet all eligibility criteria 5. Has undergone a cardiac work-up and received cardiac clearance two months before first treatment 6. Has halted use of any anticoagulants or other blood thinners (including but not limited to heparin or warfarin) within five (5) days of each treatment. 7. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) v5 grade ≤ 1. 8. Measurable disease by RECIST. 9. Able to undergo general anesthesia or conscious sedation. 10. Eastern Cooperative Oncology Group (ECOG) performance status of \< 3. 11. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the study.Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must be on stable doses for at least 42 days prior to the cryolysis 12. In the opinion of the Investigator, there is no other meaningful life-prolonging therapy option available. 13. Adequate bone marrow, renal, and hepatic function, defined as follows: a. Bone marrow function without transfusion 30 days before first dosing: i. Absolute neutrophil count ≥ 1.5 x 109/L; Lymphocyte count of ≥ 1.0 x 109/L; Platelet count ≥ 100 x 109/L; ii. Hemoglobin ≥ 9.0 g/dL b. Renal function: i. Estimated glomerular filtration rate ≥30 mL/min/1.73 m2 or creatinine clearance calculated by Cockcroft-Gault equation ≥30 mL/ c. Hepatic function: i. Alanine aminotransferase ≤ 3x upper limit of normal (ULN) ii. Aspartate aminotransferase ≤ 3x ULN iii. Total bilirubin ≤ ULN or total bilirubin ≤ 1.5x ULN with direct bilirubin ≤ ULN of the laboratory in subjects with documented Gilbert's Syndrome iv. Patients with liver metastases ≤5x ULN 14. All clinically relevant toxicities related to prior anticancer therapy must have recovered to Grade ≤1 or baseline (except alopecia or ototoxicity 15. All subjects with female partners of childbearing potential must use effective contraception throughout study treatment and for 120-150 days (4-5 months) after the last dose of study intervention 16. Has at least one lesion that is demonstrable on PET/CT, CT, Ultrasound, or MRI and is accessible for injection Exclusion criteria: 1. Has a known additional malignancy that is progressing or has required active treatment in the last 3 years, excluding basal and squamous cell carcinoma 2. Has undergone major surgery within 28 days prior to enrollment and has not recovered adequately from the toxicities and/or complications 3. Has an active infection (including tuberculosis) requiring systemic therapy 4. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis 5. Has received a live vaccine within 30 days prior to enrollment 6. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first treatment 7. Has tumor volume or disease burden too great to provide for safe and/or effective treatment as determined by the Principal Investigator after consultation with Syncromune's Chief Medical Officer 8. Subjects who have metastases limited to subcutaneous regions (only skin) 9. Significant cardiac or other medical illness such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia (e.g., New York Heart Association Class 4), or history of previous heart failure. 10. Malignant pleural effusions or ascites that require immediate intervention 11. Prior history of autoimmune disease except hypothyroidism 12. Any primary or acquired immunodeficiency 13. Active COVID infection or tests positive for COVID day before or day of planned treatment 14. Known or suspected hepatitis B if active infection (subjects with chronic hepatitis B infection must have an undetectable Hepatitis B virus (HBV) viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion) 15. Known or suspected hepatitis C infection which has not been treated and cured unless currently on treatment with an undetectable viral load 16. Prior history of autoimmune disease except hypothyroidism, uncontrolled or unmanaged diabetes, cardiac arrhytmia (unstable or untreated), hypersensitivity, or other illness or disease that in the opinion of the Principal Investigator, with consultation with Syncromune's Chief Medical Officer, makes the subject a poor candidate.Any condition(s) that, in the opinion of the Investigator, would increase the risk for toxicities from study drug, interfere with subject compliance or conduct of this study